Polyadenylation inhibition by the triphosphates of deoxyadenosine analogues.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis

• Publication date

  2008-10-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.leukres.2008.03.010PMID 18433867PMCID PMC4048126
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• RNA‐directed agent, cordycepin, induces cell death in multiple myeloma cells

  2008cited by this paper
• Mechanism of poly(A) polymerase: structure of the enzyme-MgATP-RNA ternary complex and kinetic analysis.

  2007cited by this paper
• Discovery and development of clofarabine: a nucleoside analogue for treating cancer

  2006cited by this paper
• Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.

  2005cited by this paper
• Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications.

  2005cited by this paper
• Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.

  2005cited by this paper
• Eukaryotic mRNA 3' processing: a common means to different ends.

  2005cited by this paper
• Mechanisms of Cell Death of Chronic Lymphocytic Leukemia Lymphocytes by RNA-Directed Agent, 8-NH2-Adenosine

  2005cited by this paper
• Chain Termination and Inhibition of Saccharomyces cerevisiae Poly(A) Polymerase by C-8-modified ATP Analogs*

  2004cited by this paper
• Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia.

  2004cited by this paper
• Biochemical and structural insights into substrate binding and catalytic mechanism of mammalian poly(A) polymerase.

  2004cited by this paper
• Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.

  2003cited by this paper
• Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.

  2003cited by this paper
• 2-Chloro-2′-deoxyadenosine inhibits DNA repair synthesis and potentiates UVC cytotoxicity in chronic lymphocytic leukemia B lymphocytes

  2002cited by this paper
• Faculty Opinions recommendation of A novel nuclear human poly(A) polymerase (PAP), PAP gamma.

  2002cited by this paper
• A Novel Nuclear Human Poly(A) Polymerase (PAP), PAPγ*

  2001cited by this paper
• The cap-to-tail guide to mRNA turnover

  2001cited by this paper
• Polyadenylate polymerase enzymatic activity in mammary tumor cytosols: A new independent prognostic marker in primary breast cancer.

  2000cited by this paper
• Nucleotide Requirements for the in Vitro Activation of the Apoptosis Protein-activating Factor-1-mediated Caspase Pathway*

  2000cited by this paper
• Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria.

  2000cited by this paper
• Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine

  2000cited by this paper
• The effect of p53 dysfunction on purine analogue cytotoxicity in chronic lymphocytic leukaemia

  1999cited by this paper
• Purine analogues kill resting lymphocytes by p53‐dependent and ‐independent mechanisms

  1999cited by this paper
• Tailing and 3'-end labeling of RNA with yeast poly(A) polymerase and various nucleotides.

  1998cited by this paper
• Processivity of the Saccharomyces cerevisiae Poly(A) Polymerase Requires Interactions at the Carboxyl-Terminal RNA Binding Domain

  1998cited by this paper
• Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia.

  1998cited by this paper
• Induction of an apoptotic program in cell-free extracts by 2-chloro-2'-deoxyadenosine 5'-triphosphate and cytochrome c.

  1998cited by this paper
• Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.

  1997cited by this paper
• Starting at the beginning, middle, and end: translation initiation in eukaryotes.

  1997cited by this paper
• Mechanism and regulation of mRNA polyadenylation.

  1997cited by this paper
• Fludarabine ability to down‐regulate Bcl‐2 gene product in CD5+ leukaemic B cells: in vitro/in vivo correlations

  1997cited by this paper
• Role of polyadenylation in nucleocytoplasmic transport of mRNA

  1996cited by this paper
• Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.

  1995cited by this paper
• In vitro transcription of DNA containing 2-chloro-2'-deoxyadenosine monophosphate.

  1995cited by this paper
• Degradation of mRNA in eukaryotes.

  1995cited by this paper
• Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies.

  1993cited by this paper
• Ara-ATP impairs 3'-end processing of pre-mRNAs by inhibiting both cleavage and polyadenylation.

  1991cited by this paper
• Cloning and expression of the essential gene for poly(A) polymerase from S. cerevisiae

  1991cited by this paper
• Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.

  1991cited by this paper
• Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.

  1991cited by this paper
• Incorporation of 2-halogeno-2'-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta.

  1990cited by this paper
• Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.

  1990cited by this paper
• Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells.

  1989cited by this paper
• Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase.

  1988cited by this paper
• 9-beta-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma.

  1986cited by this paper
• 9-β-D-Arabinofuranosyl-2-fluoroadenine 5′-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma

  1986cited by this paper
• Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes.

  1985cited by this paper
• Polyadenylic acid polymerase activity in normal and leukemic human leukocytes.

  1984cited by this paper
• Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.

  1983cited by this paper
• Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes

  1983cited by this paper
• In vitro biological activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine and the biochemical actions of its triphosphate on DNA polymerases and ribonucleotide reductase from HeLa cells.

  1982cited by this paper
• Specific inhibition of chromatin-associated poly(A) synthesis in vitro by cordycepin 5′-triphosphate

  1977cited by this paper
• The polyadenylate polymerases from yeast.

  1975cited by this paper
• Identification and Functional Characterization of Neo-Poly(A) Polymerase, an RNA Processing Enzyme Overexpressed in Human Tumors

  year unknowncited by this paper

• Modification of N-hydroxycytidine yields a novel lead compound exhibiting activity against the Venezuelan equine encephalitis virus.

  2023cites this paper
• Therapeutic use of fluorinated nucleosides - progress in patents.

  2018cites this paper
• Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology

  2017cites this paper
• Fluorinated nucleosides as an important class of anticancer and antiviral agents.

  2017cites this paper
• Base-modified thymidine and thymine analogs with low cytotoxicity effectively obstruct DNA replication in papovaviridae

  2016cites this paper
• Base-Modified Nucleosides as Chemotherapeutic Agents: Past and Future.

  2016cites this paper
• Base-modified thymidines capable of terminating DNA synthesis are novel bioactive compounds with activity in cancer cells.

  2015cites this paper
• Nonviral gene delivery to the liver

  2015cites this paper
• Studies of overcoming acquired resistance : molecular mechanisms and development of novel drugs

  2014cites this paper
• Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: relevance of p53 and its clinical implications.

  2013cites this paper
• Clofarabine (2-chloro-2'-fluoro-2'-deoxyarabinosyladenine)--biochemical aspects of anticancer activity.

  2011cites this paper
• Cladribine inhibits cytokine secretion by T cells independently of deoxycytidine kinase activity.

  2011cites this paper
• Liquid chromatographic methods for the determination of endogenous nucleotides and nucleotide analogs used in cancer therapy: a review.

  2010cites this paper
• Interstrand crosslink inducing agents in pretransplant conditioning therapy for hematologic malignancies

  2010cites this paper
• The cladribine conundrum: deciphering the drug's mechanism of action

  2010cites this paper
• Influence of clofarabine on transcriptional activity of PTEN, APC, RARB2, ZAP70 genes in K562 cells.

  2010cites this paper
• Chain termination and inhibition of mammalian poly(A) polymerase by modified ATP analogues.

  2010cites this paper
• Mechanisms of anti-cancer action and pharmacology of clofarabine.

  2009influential citation
• Clofarabine: emerging role in leukemias

  2009cites this paper